RxDoctor Payments Data

Niel Dave, MD

Gastroenterology · Avondale, AZNPI 1487187761

Payments from drug & device makers

$22,598in general payments, 2019–2025

Across 288 payments — averaging $78.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$16K
  • AbbVie$976
  • Sanofi$649
  • Gilead$615
  • Takeda Pharmaceuticals U.S.A., Inc.$592
  • Johnson & Johnson$568
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$15,05067%
  • Travel & lodging$2151%
  • Food & beverage$7,24332%
  • Education$900%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,598 in reported general payments places this provider in the 75th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$108,667
Medicare patients
272
Services billed
1,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase14$42,164
LinzessLinaclotide52$40,250
TrulancePlecanatide34$20,416
VoqueznaVonoprazan Fumarate25$20,169
Esomeprazole Magnesium161$8,243
MotegrityPrucalopride Succinate11$5,673
Pantoprazole Sodium289$3,611
CholestyramineCholestyramine (With Sugar)14$2,247
Ondansetron Hcl36$1,743
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C12$1,741
Colestipol Hcl18$1,640
Famotidine119$1,480
Ondansetron OdtOndansetron24$992
Lubiprostone13$939
Omeprazole43$747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$976$82,41466 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$404$22,15746 claims
Phathom Pharmaceuticals, Inc.Voquezna$16,115$20,16925 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$592$5,67311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Avondale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →